18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas

Journal of Nuclear Medicine

Volumn 48, Issue 3, 2007, Pages 367-372

  Been, Lukas B ^a   Suurmeijer, Albert J H ^a   Elsinga, Philip H ^a   Jager, Pieter L ^a   Van Ginkel, Robert J ^a   Hoekstra, Harald J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

18F FLT PET; Hyperthermic isolated limb perfusion; Soft tissue sarcomas

Indexed keywords

FLUORODEOXYTHYMIDINE F 18; TRACER; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; FLUORINE; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIMB PERFUSION; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; CRYOANESTHESIA; LIMB; MIDDLE AGED; SARCOMA; SCINTISCANNING; VASCULARIZATION;

ADULT; AGED; DIDEOXYNUCLEOSIDES; EXTREMITIES; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; HYPOTHERMIA, INDUCED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SARCOMA;

EID: 34247201668     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95:1276-1299.
2. Ham SJ, van der Graaf WT, Pras E, Molenaar WM, van den Berg E, Hoekstra HJ. Soft tissue sarcoma of the extremities: a multimodality diagnostic and therapeutic approach. Cancer Treat Rev. 1998;24:373-391.
3. Guchelaar HJ, Hoekstra HJ, de Vries EG, Uges DR, Oosterhuis JW, Schraffordt KH. Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities. Br J Cancer. 1992;65:898-902.
4. Noorda EM, Vrouenraets BC, Nieweg OE, van Coevorden F, van Slooten GW, Kroon BB. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer. 2003;98:1483-1490.
5. Lejeune FJ, Pujol N, Lienard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol. 2000;26:669-678.
6. Eggermont AM, Schraffordt KH, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg. 1996;224:756-764.
7. Gutman M, Inbar M, Lev-Shlush D, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 1997;79:1129-1137.
8. Thijssens KM, van Ginkel RJ, Pras E, Suurmeijer AJ, Hoekstra HJ. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy. Ann Surg Oncol. 2006;13:518-524.
9. Zwaveling JH, Maring JK, Mulder AB, et al. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system. Cancer Res. 1996;56:3948-3953.
10. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
11. 18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging. 2004;31:1659-1672.
12. Cobben DC, Elsinga PH, Suurmeijer AJ, et al. Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′- deoxy-L-thymidine. Clin Cancer Res. 2004;10:1685-1690.
13. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004;45:695-700.
14. Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616-632.
15. Daryanani D, Komdeur R, Ter Veen J, Nijhuis PH, Piers DA, Hoekstra HJ. Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol. 2001;8:566-572.
16. Hoekstra HJ, Daryanani D, van Ginkel RJ. Isolated limb perfusion. In: Van Schil P, ed. Lung Metastases and Isolated Lung Perfusion. Hauppauge, NY: Nova Science Publishers, Inc.; In press.
17. Zwaveling JH, Hoekstra HJ, Maring JK, et al. Renal function in cancer patients treated with hyperthermic isolated limb perfusion with recombinant tumor necrosis factor-alpha and melphalan. Nephron. 1997;76:146-152.
18. Coindre JM, Trojani M, Contesso G, et al. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer. 1986;58:306-309.
19. Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson JR. Simplified labeling approach for synthesizing 3′-deoxy-3′-[F-18] fluorothymidine ([F-18]FLT). J Radioanal Nucl Chem. 2000;243:843-846.
20. Lonneux M, Borbath I, Bol A, et al. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. Eur J Nucl Med. 1999;26:591-598.
21. Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18]fluoro- 3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36-42.
22. 18F-FLT positron emission tomography for imaging non-Hodgkin's lymphoma and assessment of proliferative activity [abstract]. J Nucl Med. 2003;44(suppl):188P-189P.
23. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8:3315-3323.
24. 18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res. 2003;63:2681-2687.
25. Issakov J, Merimsky O, Gutman M, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations. Ann Surg Oncol. 2000;7:155-159.
26. Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev. 2004;30:83-101.
27. 18F-FDG PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med. 1996;37:984-990.
28. 11C]-Tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. J Nucl Med. 1999;40:262-267.